3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
18
Carcinoma, Hepatocellular
9
Neoplasms
8
Melanoma
7
Squamous Cell Carcinoma of Head and Neck
6
Nasopharyngeal Carcinoma
6
Triple Negative Breast Neoplasms
5
Esophageal Neoplasms
5
Neoplasm Metastasis
4
Esophageal Squamous Cell Carcinoma
4
Colonic Neoplasms
4
Recurrence
3
Rectal Neoplasms
3
Pancreatic Neoplasms
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Stomach Neoplasms
2
Solid Cancers
2
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Gastric / Gastroesophageal Junction Adenocarcinoma
2
EBV-associated Tumors
2
Cholangiocarcinoma
2
Breast Neoplasms
2
Bites and Stings
2
Biliary Tract Neoplasms
2
Advanced Solid Tumors
2
Interventions
pembrolizumab
45
Paclitaxel
42
Carboplatin
34
Bevacizumab
18
Specimen Handling
17
Letrozole
16
lenvatinib
13
Magnetic Resonance Spectroscopy
12
dostarlimab
11
Cisplatin
11
Biopsy
11
Taxes
10
olaparib
9
Fulvestrant
9
Doxorubicin
9
abemaciclib
8
Megestrol Acetate
8
Docetaxel
8
durvalumab
7
atezolizumab
7
Nivolumab
7
Gemcitabine
7
Blood Specimen Collection
7
palbociclib
6
Oxaliplatin
6
Observation
6
Fluorouracil
6
niraparib
5
Surveys and Questionnaires
5
Progestins
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
Immune Checkpoint Inhibitors
×
1 year
×
Clear all
NCT06710847
2026-02-02
SYLVER
GlaxoSmithKline
Phase 1/2
Active not recruiting
14 enrolled